02193nas a2200241 4500000000100000008004100001260001200042653001900054653001900073653001200092653000900104653003900113100001500152700001400167700001500181700001200196700001200208700001300220245012900233300001100362520156400373022001401937 2021 d c02/202110aCyclooxygenase10aLepra Reaction10aleprosy10aSkin10aVascular Endothelial Growth Factor1 aMalhotra K1 aSuvirya S1 aMalhotra H1 aKumar B1 aKumar S1 aHusain N00aCyclooxygenase 2 and Vascular Endothelial Growth Factor - potential targets to manage lepra reactions: A case-control study. ae148823 a

BACKGROUND: Reactions in leprosy have an immune mediated pathogenesis. While type 1 reactions are delayed hypersensitivity phenomenon, type 2 reactions are immune complex mediated. Key molecules which mediate the immune insult in lepra reactions require evaluation in order to tailor their therapy and prevent disability.

OBJECTIVE: To evaluate expressions of Cyclooxygenase 2 and Vascular Endothelial Growth Factor in skin biopsies from leprosy patients and correlate their expression with presence of either type 1 or type 2 lepra reactions.

METHODS: This was a case control study. Cyclooxygenase 2 and Vascular Endothelial Growth Factor expression in dermal macrophages and vascular endothelium was assessed immunohistochemically. Biopsies from patients with Non-reactive leprosy and healthy controls were used for comparison. SPSS software was used for statistical analysis.

RESULTS: A total of 147 skin biopsies were evaluated, including 18 with Type 1 reaction, 39 Type 2 reaction, 81 non-reactive leprosy and 9 healthy controls. Both Cyclooxygenase 2 and Vascular Endothelial Growth Factor expression were significantly higher in type 1 followed by type 2 reaction as compared to controls.

CONCLUSION: These results may guide us regarding use of Cyclooxygenase 2 and Vascular Endothelial Growth Factor inhibitor drugs which may be a major step in treating reactive leprosy patients and preventing nerve damage and disability. This article is protected by copyright. All rights reserved.

 a1529-8019